The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the editor
Editor, – I refer to the comment on tacrolimus published recently in your 'New drugs' section (Aust Prescr 1998;21:81-2).
The study referred to was published in 1994 as the preliminary experience of 8 respected European centres.
Follow-up data from the same trial has been subsequently published.1 This latter report describes a similar safety profile of tacrolimus compared with cyclosporin, but with a less problematic convalescence. It is stressed that careful attention to dosing and blood level assessment is necessary. Concentrations of both tacrolimus and cyclosporin require routine post-transplant monitoring, both are metabolised by cytochrome P450 and both have similar drug interactions. Toxicity of both agents is largely dose related. In the earlier study, blood levels of tacrolimus were not available at the time of dose adjustments and the doses initially recommended were inappropriately high. Continuous infusion of tacrolimus was used initially and this practice has now been abandoned by most programs because of the recognised greater toxicity of the parenterally administered drug.
The comparison between cyclosporin and tacrolimus has less relevance in 1998 as the former has been largely replaced with the microemulsified version of cyclosporin. This new formulation and tacrolimus are both well absorbed from the gut immediately after transplantation.
Stephen V. Lynch
Associate Professor of Surgery
Queensland Liver Transplant Service
Royal Children's Hospital
The Pharmaceutical Benefits Pricing Authority's Therapeutic Relativity Sheets (August 1998) state 'Tacrolimus was accepted as being more effective than cyclosporin and less costly'.
- Williams R, Neuhaus P, Bismuth H, McMaster P, Pichlmayr R, Caine R, et al. Two-year data from the European multi centre tacrolimus (FK506) liver study. Transpl Int 1996;9(1 Suppl):144S-150S.